Bibliography
- Berg K : A new serum type system in man – the LP system.Acta Pathol. Microbiol. Scand.59, 369–382 (1963).
- Utermann G : Lipoprotein(a). In: The Metabolic and Molecular Bases of Inherited Disease (2001 Edition). ScriverCR, BeaudetAL, SlyWS, ValleD (Eds). McGraw-Hill, Medical Publishing Division, NY, USA, 2753–2787 (2006).
- Deb A , CapliceNM: Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis.Clin. Cardiol.27(5), 258–264 (2004).
- Boffa MB , MarcovinaSM, KoschinskyML: Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.Clin. Biochem.37(5), 333–343 (2004).
- Nielsen LB , JuulK, NordestgaardBG: Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation.Arterioscler. Thromb. Vasc. Biol.18(4), 641–649 (1998).
- Edelstein C , PfaffingerD, HinmanJet al. : Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a).J. Biol. Chem.278(52), 52841–52847 (2003).
- Tsimikas S , BrilakisES, MillerERet al. : Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.N. Engl. J. Med.353(1), 46–57 (2005).
- Nielsen LB , Gr⊘nholdtML, SchroederTV, StenderS, NordestgaardBG: In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima.Arterioscler. Thromb. Vasc. Biol.17(5), 905–911 (1997).
- Alfthan G , PekkanenJ, JauhiainenMet al. : Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.Atherosclerosis106(1), 9–19 (1994).
- Ridker PM , HennekensCH, StampferMJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction.JAMA270(18), 2195–2199 (1993).
- Craig WY , NeveuxLM, PalomakiGE, ClevelandMM, HaddowJE: Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies.Clin. Chem.44(11), 2301–2306 (1998).
- Danesh J , CollinsR, PetoR: Lipoprotein(a) and coronary heart disease – meta-analysis of prospective studies.Circulation102(10), 1082–1085 (2000).
- Erqou S , KaptogeS, PerryPLet al. : Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.JAMA302(4), 412–423 (2009).
- Danik JS , RifaiN, BuringJE, RidkerPM: Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.JAMA296(11), 1363–1370 (2006).
- Kamstrup PR , BennM, Tybjærg-HansenA, NordestgaardBG: Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.Circulation117(2), 176–184 (2008).
- Kamstrup PR , Tybjærg-HansenA, SteffensenR, NordestgaardBG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.JAMA301(22), 2331–2339 (2009).
- Clayton D , McKeiguePM: Epidemiological methods for studying genes and environmental factors in complex diseases.Lancet358(9290), 1356–1360 (2001).
- Smith GD , EbrahimS: Mendelian randomization: prospects, potentials, and limitations.Int. J. Epidemiol.33(1), 30–42 (2004).
- Zacho J , Tybjærg-HansenA, JensenJS, GrandeP, SillesenH, NordestgaardBG: Genetically elevated C-reactive protein and ischemic vascular disease.N. Engl. J. Med.359(18), 1897–1908 (2008).
- Holmer SR , HengstenbergC, KraftHGet al. : Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction.Circulation.107(5), 696–701 (2003).
- Sandholzer C , SahaN, KarkJDet al. : Apo(a) isoforms predict risk for coronary heart disease. A study in six populations.Arterioscler. Thromb.12(10), 1214–1226 (1992).
- Kraft HG , LingenhelA, KochlSet al. : Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease.Arterioscler. Thromb. Vasc. Biol.16(6), 713–719 (1996).
- Kamstrup PR , Tybjærg-HansenA, SteffensenR, NordestgaardBG: Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease.J. Clin. Endocrinol. Metab.93(10), 3769–3776 (2008).
- Carlson LA , HamstenA, AsplundA: Pronounced lowering of serum levels of lipoprotein Lp(A) in hyperlipemic subjects treated with nicotinic-acid.J. Intern. Med.226(4), 271–276 (1989).